Transaction DateRecipientSharesTypePriceValue
17th August 2020Laurent Fischer7,692Open or private purchase$13.00$99,996.00
17th August 2020Peter Soparkar7,692Open or private purchase$13.00$99,996.00
20th July 2020Mehdi Gasmi5,000Exercise of derivative$4.80$24,000.00
20th July 2020Mehdi Gasmi5,000Open or private sale$17.60$87,978.00
22nd June 2020Mehdi Gasmi23,605Open or private sale$25.06$591,616.84
22nd June 2020Mehdi Gasmi23,605Exercise of derivative$4.80$113,304.00
18th June 2020Mehdi Gasmi11,127Open or private sale$25.01$278,328.55
18th June 2020Mehdi Gasmi11,127Exercise of derivative$4.80$53,409.60
17th June 2020Mehdi Gasmi268Open or private sale$25.01$6,702.71
17th June 2020Mehdi Gasmi268Exercise of derivative$4.80$1,286.40
Avalanche Biotechnologies
Avalanche Biotechnologies logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Ticker: AAVL
Sector: Unknown
Industry: Unknown
SEC Central Index Key (CIK): 1501756
Exchange: None
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $27 M (-58%)
Assets, Current: $283 M (60%)
Property, Plant and Equipment, Net: $27 M (0%)
Other Assets, Noncurrent: $19 Th (72%)
Assets: $331 M (48%)
Accounts Payable, Current: $10 M (152%)
Liabilities, Current: $21 M (9%)
Other Liabilities, Noncurrent: $101 Th (-31%)
Liabilities: $49 M (1%)
Common Stock, Value, Issued: $8 Th (14%)
Additional Paid in Capital, Common Stock: $720 M (28%)
Retained Earnings (Accumulated Deficit): $437 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $598 Th (-17%)
Stockholders' Equity (Parent): $283 M (0%)
Liabilities and Equity: $331 M (48%)
Research and Development: $19 M (-43%)
General and Administrative Expenses: $11 M (-46%)
Operating Income/Loss: $30 M (-44%)
Other Income, net: $575 Th (-60%)